MNKD vs ORMP
MNKD: MannKind is a biopharmaceutical company specializing in inhaled therapeutic platforms and on-body infusion delivery systems for endocrine and pulmonary conditions. ORMP: A pharmaceutical company pioneering oral protein delivery technology while leveraging a strategic investment portfolio to generate shareholder value.
Side-by-side fundamentals
| Metric | MNKD | ORMP | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $3.10 | $4.15 | |
| Market cap | $997M | $173M | |
| P/E as of 2026-10-20 | n/a | 1.00 (earnings are mostly non-operating: 107% of trailing pre-tax income, to 2026-06-30) | |
| Net margin FY2025, SEC XBRL | +1.7% | n/a | |
| Gross margin FY2025, SEC XBRL | n/a | +0.7% | |
| Operating margin FY2025, SEC XBRL | +11.1% | -754.4% | MNKD higher |
| ROE FY2025, SEC XBRL | n/a | +32.1% | |
| ROA FY2025, SEC XBRL | +0.7% | +27.7% | ORMP higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +22.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +51.8% | -7.3% | MNKD higher |
| Dividend streak (yrs) SEC XBRL | 0 | 1 | ORMP higher |
| Beta as of 2026-09-03 | 0.69 | 0.64 | |
| 1-year return as of 2026-10-20 close | -43.5% | +81.2% | ORMP higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.